We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Kate
Newbold
kate.newbold@rmh.nhs.uk
Ms
Yvonne
Fox-Miller
nucmedresearch@rmh.nhs.uk
Malignant neoplasms of thyroid and other endocrine glands
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Differentiated thyroid cancer (DTC) is the most common endocrine cancer, with a UK incidence of around 3,500 per year. Treatment with radioactive iodine following surgery has been standard for over 70 years. Nevertheless, there remains controversy over the optimal amount of radioactivity to administer, which varies in different countries from none to 3700 MBq.
The hypothesis underlying this proposal is that treatment outcome is dependent on the radiation doses delivered to the remaining thyroid tissue. These doses will depend on the local biodistribution of the iodine and not only from the amount of radioactivity administered. Recent developments in hardware and methodology now enable this biodistribution to be quantitatively assessed.
An ongoing CRUK/AZ funded study (SEL-I-METRY) has created the first network of UK centres that are able to perform these standardised quantitative assessments. The Royal Marsden hospital is the lead centre with respect to this network and as such has developed considerable expertise in this area. In parallel, a European (Horizon 2020) funded study (MEDIRAD) has begun to record measurements of radioiodine biodistribution at European centres in Germany and France. These centres have been set up for quantitative imaging as for the UK SEL-I-METRY study.
This is a non-interventional observational study which will not affect patient treatment. Post treatment imaging assessments of radioiodine uptake will be made using gamma cameras set up to quantify the amount of radioactivity observed. Patients will be followed-up at their standard-of-care clinic visits to assess the success of treatment as well as for short to mid-term toxicity.
Analysis of the radioiodine imaging data will be carried out to establish the range of radiation doses to remaining thyroid tissue as well as normal organs. Analysis of the relationship between these doses and outcome data will be performed.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of outcome measures;
You can take part if:
You may not be able to take part if:
o External radiotherapy in the last 6 weeks o Systematic chemotherapy in the last 6 weeks o Pregnancy or breast feeding
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by THE ROYAL MARSDEN NHS FOUNDATION TRUST and funded by European Commission .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 44418
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
